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Background: All-trans retinoic acid (ATRA, tretinoin) is a vitamin A derivative commonly used in the treatment of
diverse conditions ranging from cancer to acne. In a fraction of predisposed individuals, the administration of ATRA
is accompanied by variety of adverse metabolic effects, particularly by the induction of hyperlipidemia. We have
previously derived a minimal congenic SHR.PD-(D8Rat42-D8Arb23)/Cub (SHR-Lx) strain sensitive to ATRA-induced
increase of triacylglycerols and cholesterol under condition of high-sucrose diet. SHR-Lx differs only by 7 genes of
polydactylous rat (PD/Cub) origin from its spontaneously hypertensive rat (SHR) progenitor strain.
Methods: Adult male rats of SHR and SHR-Lx strains were fed standard diet (STD) and experimental groups were
subsequently treated with ATRA (15 mg/kg) via oral gavage for 16 days, while still on STD. We contrasted the
metabolic profiles (including free fatty acids, triacylglycerols (TG) and cholesterol (C) in 20 lipoprotein fractions)
between SHR and SHR-Lx under conditions of standard diet and standard diet + ATRA. We performed transcriptomic
analysis of muscle tissue (m. soleus) in all groups using Affymetrix GeneChip Rat Gene 2.0 ST Arrays followed by
Ingenuity Pathway Analysis and real-time PCR validation.
Results: In response to ATRA, SHR-Lx reacted with substantially greater rise in TG and C concentrations throughout
the lipoprotein spectrum (two-way ANOVA strain * RA interaction significant for C content in chylomicrons (CM),
VLDL and LDL as well as total, CM and HDL-TG).
Conclusions: According to our modeling of metabolic and signalization pathways using differentially expressed
genes we have identified a network with major nodes (including Sirt3, Il1b, Cpt1b and Pparg) likely to underlie the
observed strain specific response to ATRA.
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Zbtb16Background
All-trans-retinoic acid (ATRA, tretinoin) is a vitamin A
derivative that serves as a prominent hub of many
signaling and metabolic pathways involved in range of
processes from development to energy homeostasis [1].
Both excess and shortage of ATRA were shown to have
pathophysiological consequences and rather tight main-
tenance of ATRA levels is necessary both in development
and adult life in order to prevent disease manifestation
[2]. Apart from its well described role as a teratogen,* Correspondence: oseda@lf1.cuni.cz
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unless otherwise stated.variety of side-effects associated with ATRA therapy in
postnatal stages of life have been described both for
topical [3] and systemic administration [4]. Serum con-
centrations of lipids [5,6], glucose tolerance or bone
metabolism [7] are among the systems most frequently
affected in adverse reactions to ATRA administration. On
the other hand, several recent studies suggested the poten-
tial of tretinoin and other, more specific retinoid receptor
agonists in treatment of metabolic syndrome or its com-
ponents [8,9]. We have previously established a congenic
rat strain SHR.PD(D8Rat42-D8Arb23)/Cub (SHR-Lx
hereafter) particularly sensitive to teratogenic actions of
ATRA [10] as well as ATRA-induced dyslipidemia when
fed high-sucrose diet [11]. The SHR-Lx is also insulin
resistant compared to its spontaneously hypertensive ratal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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region of chromosome 8. While in the original work we
assigned 14 protein-coding genes to the differential
segment present in SHR-Lx [12], we have recently fine
mapped its span to less than 800 kb encompassing only
seven genes [13]. In the current study, we have investi-
gated whether the sensitivity of SHR-Lx to ATRA-induced
dyslipidemia is present also under standard diet condition.
At the same time, we explored whether the pharmaco-
genetic interaction of RA and the differential segment is
reflected in the transcriptome of skeletal muscle, the tissue
shown to be metabolically challenged in the SHR-Lx [12].
Results
Morphometric profile
When fed standard diet, both strains showed comparable
body weight and relative weights of visceral and retroperi-
toneal adipose tissue depots. The liver and kidney weights
were lower in SHR-Lx congenic, on the contrary, weight
of adrenals was increased in comparison to SHR (Table 1).
The 16-day RA administration did not result in changes
of total body weight (repeated measures ANOVA was
insignificant for Strain, ATRA and Strain* ATRA) or
adipose tissue depots in either of the strains. The ATRA-
treated SHR showed significantly higher relative weights of
liver, heart and kidneys compared to ATRA-treated SHR-
Lx. The only morphometric effect attributable to RA was
increase of liver weight per 100 g body weight exclusively
in SHR (Table 1). The fasting glycemia did not vary signifi-
cantly regardless of strain or ATRA administration status.
Detailed lipid profile
The control SHR rats had significantly higher total and
chylomicron TG levels compared to STD-fed SHR-Lx
(Table 2). The ATRA administration resulted in substantial
increase of triacylglycerol concentrations in all major lipo-
protein fractions except LDL exclusively in SHR-Lx




Body weight, g 294 ± 6
Liver, g/100 g b.wt. 3.73 ± 0.08
Heart, g/100 g b.wt. 0.40 ± 0.01
Kidney, g/100 g b.wt. 0.711 ± 0.003
Adrenals, mg/100 g b.wt. 14.1 ± 0.3
EFP wt., g/100 g b.wt. 0.89 ± 0.03
RFP wt., g/100 g b.wt. 1.05 ± 0.06
Morphometric profile of SHR vs. SHR-Lx rats. The significance levels are indicated as
between SHR and SHR-Lx under conditions of a single diet; †…p <0.01, respectively
b.wt….body weight; EFP…epididymal fat pad; RFP…retroperitoneal fat pad.concentrations were higher in the ATRA-treated congenics
compared to SHR (Table 2, Figure 1). We observed similar
pattern for cholesterol distribution across the lipoprotein
spectrum, reflected by significant Strain * ATRA interac-
tions for chylomicron, VLDL and LDL cholesterol (Tables 2
and 3). So, while total cholesterol as well as cholesterol
concentration in all major lipoprotein classes were signifi-
cantly higher in control SHR rats compared to SHR-Lx
controls, chylomicron and VLDL-C substantially increased
only in SHR-Lx to levels significantly higher than those in
SHR (Table 2, Figure 2). LDL-C actually slightly decreased
only in ATRA-treated SHR, the HDL-C did not change in
either of the strains and remained thus lower in the SHR-
Lx. No differences were observed for fasting glycerol
regardless of strain or ATRA status. The sizes of VLDL,
LDL and HDL particles were similar in STD-fed animals of
both strains. The treatment with ATRA induced increases
of VLDL and LDL particle sizes together with a decrease
of HDL size only in the SHR-Lx, resulting in their signifi-
cant difference from the unchanged SHR values (Table 4).
Transcriptomic profile of skeletal muscle
In order to generate testable hypothesis on potential
mechanism of the observed pharmacogenetic inter-
action, we have searched for distinct patterns of tran-
scription changes in skeletal muscle. The canonical
pathway enrichment showed only 4 significant results.
The single pathway exclusively enriched in context of
ATRA effect on SHR was Ethanol degradation (Benjamini-
Hochberg (B-H) p = 6.88 × 10-3, including SHR-exclusive
downregulation of Aldh3a1), the remaining three pathways
were overrepresented only in context of ATRA effect on
SHR-Lx: D-myo-inostitol (1,4,5)-triphosphate degradation
(B-H p = 1.83 × 10-3), Eicosanoid signaling (B-H p = 3.81 ×
10-2) and Role of macrophages, fibroblasts and endothelial
cells in rheumatoid arthritis (B-H p = 1.83 × 10-3 including
upregulation of Il1b). Next we generated networks based
on the transcript sets showing the highest significance forStandard diet + ATRA
SHR-Lx SHR SHR-Lx
(n = 7) (n = 7) (n = 8)
275 ± 8 284 ± 7 265 ± 10
3.53 ± 0.05a 4.04 ± 0.09† 3.72 ± 0.03b
0.40 ± 0.02 0.41 ± 0.01 0.37 ± 0.01a
0.65 ± 0.01c 0.71 ± 0.01 0.66 ± 0.01b
15.7 ± 0.4b 14.4 ± 0.3 14.8 ± 0.4
0.84 ± 0.03 0.88 ± 0.03 0.83 ± 0.04
0.92 ± 0.05 1.02 ± 0.06 0.90 ± 0.06
follows: a, b, c…p <0.05 and 0.01 and 0.001, respectively for differences
, for RA effect within individual strain. Values are shown as mean ± S.E.M.;
Table 2 Major triacylglycerol, cholesterol subfractions and free glycerol comparison between control and retinoic
acid-fed SHR vs. SHR-Lx rats
Trait (mg/dl) Standard diet Standard diet + ATRA
SHR SHR-Lx SHR SHR-Lx
(n = 7) (n = 7) (n = 7) (n = 8)
Triacylglycerol (TG)
Total TG 61.84 ± 4.50 46.33 ± 2.38a 69.87 ± 5.51 77.27 ± 4.66‡
Chylomicron TG 7.97 ± 0.83 3.66 ± 0.34a 8.47 ± 1.05 11.94 ± 0.67‡,b
VLDL-TG 37.27 ± 3.28 27.68 ± 2.05 42.67 ± 4.11 44.83 ± 4.37†,a
LDL-TG 12.29 ± 0.47 12.04 ± 0.39 14.07 ± 0.85 14.28 ± 1.12
HDL-TG 4.32 ± 0.13 2.95 ± 0.12 4.66 ± 0.36 6.23 ± 0.99‡
Cholesterol (C)
Total C 45.92 ± 1.57 38.46 ± 1.55c 42.52 ± 1.34 40.26 ± 0.78
Chylomicron C 0.63 ± 0.05 0.29 ± 0.02c 0.69 ± 0.07 1.18 ± 0.20 ‡,b
VLDL-C 3.26 ± 0.27 2.32 ± 0.10 a 3.70 ± 0.22 5.10 ± 0.46‡,b
LDL-C 11.26 ± 0.44 9.10 ± 0.31c 9.77 ± 0.37* 9.78 ± 0.39
HDL-C 30.77 ± 1.38 26.75 ± 1.37a 28.37 ± 1.20 24.20 ± 0.94a
Glycerol 1.07 ± 0.12 1.00 ± 0.06 1.24 ± 0.15 0.99 ± 0.02
Data are shown as mean ± S.E.M. The significance levels are indicated as follows: a, b, c…p <0.05, 0.01 and 0.001, respectively for differences between SHR and
SHR-Lx under conditions of a single diet; †, ‡… p <0.01 and 0.001, respectively, for RA effect within individual strain.
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ing network reaching the highest score is shown in Figure 3.
In addition to retinoid receptors it contains and connects
number of genes with known involvement in lipid metab-
olism, insulin resistance and inflammation. Then we
explored the shortest possible connection of the identified
network to all seven genes present in the differential
segment of SHR-Lx. The only gene with identifiable
connection to the network was Zbtb16 (Figure 3). We have
subsequently validated the microarray results using real-
time PCR for several major transcripts showing distinct
patterns the expression changes and at the same time
representing major nodes identified by the network
analysis (Additional file 1: Figure S1). In all cases we were
able to corroborate the “direction” of the RA-induced
effect, i.e. the relative up- or down-regulation of expression
in the individual strain, yet the extent of the change
seemed to be somewhat underestimated by the array.
Discussion
Induction of hyperlipidemia belongs to one of the fre-
quent side-effects of administration of retinoid receptor
agonists including ATRA to humans. Hyperlipidemia
actually belonged to the dose-limiting toxicity factor for
oral treatment of oncological conditions with rexinoids
(selective retinoic X receptor ligands), increasing par-
ticularly the triacylglycerols by hundreds of percent [14].
Even though the individual sensitivity towards the
adverse metabolic effects of retinoids is most likely
driven by particular pharmacogenetic interactions, there
is very little information available on the genetic variantsinvolved except for the treatment of several cancers
including acute promyelocytic leukemia [15], neuroblast-
oma [16] or head and neck squamous cell carcinoma
[17]. We have previously identified the mutant rat Lx
allele as a genetic variant sensitizing to ATRA-mediated
teratogenic effects [10,18,19]. During the process of
positional cloning of Lx we were eventually able to trap
the variant within a minimal differential segment in the
SHR-Lx congenic strain [13,20]. When fed high-sucrose
diet, the adult SHR-Lx rats mimicked the hyperlipidemic
reaction to ATRA exposure contrasting with its SHR
progenitor [11]. In the current study, we show this over-
sensitivity to be preserved under conditions of standard
diet feeding and thus not being dependent on diet*
medication interaction(s). This seems to be in direct
contrast with the reports from several recent studies in
C57BL/6 mice. In this murine strain, ATRA was shown
to prevent high-fat, high-sucrose diet-induced obesity
[21] and ameliorate glucose intolerance, insulin resist-
ance and even dyslipidemia [22,23]. However, apart from
possible species differences, the reason for such dispar-
ate results may as well lie in the genetically determined
susceptibility itself – the SHR control strain in our study
did not actually show any metabolic deterioration in
response to ATRA, the LDL-C levels even slightly
dropped. The SHR-Lx strain thus truly represents a
model of enhanced susceptibility found in the humans
manifesting substantial adverse effects to ATRA treatment.
We have previously established that insulin-stimulated
glucose utilization in muscle of SHR-Lx is impaired in com-
parison to SHR [12]. Given the importance of the skeletal
Figure 1 The triacylglycerol content in 20 lipoprotein subfractions in standard diet-fed (STD, open symbols) and ATRA-treated (STD+ ATRA,
closed symbols) SHR (panel A) vs. SHR-Lx (panel B) male rats (n = 7-8 / strain* treatment). Within the graph, the significance levels of strain
comparison (SHR vs. SHR-Lx) by post-hoc Tukey's honest significance difference test of the two-way ANOVA with STRAIN and ATRA as major factors
are indicated as follows: *…p < 0.05; **…p < 0.01; ***…p < 0.001. The allocation of individual lipoprotein subfractions to major lipoprotein classes is
shown in order of particle’s decreasing size from left to right. CM…chylomicron, VLDL…very low-density lipoprotein, LDL…low-density lipoprotein,
HDL…high-density lipoprotein.
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olism, we have assessed the transcriptomic correlates of the
observed pharmacogenetic interaction in the mm. solei of
both strains. The resulting network of transcripts central to
strain-specific reaction to ATRA (Figure 3) corresponds to
our biochemical findings and is suggestive concerning the
possible mechanism of SHR-Lx sensitivity. One of the im-
portant nodes connecting several modules of the network
is Sirt3, specifically downregulated by ATRA in SHR-Lx
(Additional file 1: Figure 1). Downregulation of this gene
was found in rodent models of diabetes and was reported
to impair insulin signaling in the muscle and induce oxida-
tive stress [24]; hence it was proposed as major regulator of
metabolic flexibility of skeletal muscle [25]. It is through
stearoyl-CoA desaturase (Scd1) that Sirt3 connects to anapparent lipid-related module with peroxisome proliferator
activated receptor alpha at its middle. The SHR-Lx con-
genic shows more than three- and twofold higher expres-
sion of Scd1 in control and ATRA-treated animals when
compared to SHR. As recently reviewed, increased Scd1
expression in skeletal muscle (both in transgenic models
and obese human subjects) is associated with decreased
beta-oxidation, increased TG accumulation and muscle
insulin resistance [26]. Within this lipid-related cluster, we
have validated the pronounced downregulation of Cpt1b
(a key enzyme in the control of fatty acid oxidation) in
response to ATRA in SHR-Lx. Peroxisome proliferator acti-
vated receptor gamma represents the focal point of the
whole network. Activated solely in SHR by ATRA, it pro-
vides a link between the metabolic and cell proliferation/
Table 3 Two-way analysis of variance (ANOVA) results for
morphometric and metabolic profile of SHR vs. SHR-Lx
rats with STRAIN and RA as major factors
Phenotype STRAIN ATRA S*ATRA
Body weight 0.023 0.23 0.97
Liver, g/100 g b.wt. 0.0005 0.0008 0.76
Heart, g/100 g b.wt. 0.13 0.47 0.10
Kidney, g/100 g b.wt. <0.0001 0.60 0.77
Adrenals, mg/100 g b.wt. 0.010 0.38 0.12
EFP wt., g/100 g b.wt. 0.039 0.65 0.90
RFP wt., g/100 g b.wt. 0.13 0.64 0.96
Total C 0.0018 0.56 0.07
Chylomicron C 0.48 0.0003 0.001
VLDL-C 0.43 <0.0001 0.0007
LDL-C 0.011 0.31 0.010
HDL-C 0.0035 0.06 0.96
Total TG 0.37 0.0003 0.017
Chylomicron TG 0.59 <0.0001 <0.0001
VLDL-TG 0.31 0.0049 0.12
LDL-TG 0.97 0.017 0.77
HDL-TG 0.85 0.0030 0.013
Glycerol 0.13 0.41 0.37
Fasting plasma glucose 0.15 0.08 0.76
Lipoprotein particle size
VLDL-TG 0.61 0.34 0.0075
LDL-C 0.0026 0.0013 0.07
HDL-C 0.0003 0.039 0.08
The significance levels of two-way ANOVA’s STRAIN, RA and STRAIN*RA (S*RA)
factor interactions are shown (significant p values in bold, non-significant
in italics).
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behavior in the current study. None of the 7 genes present
in the differential segment of the congenic strain were
distinctly up- or downregulated by ATRA in the soleus
muscle. However, testing the existing paths between the 7
genes and the top mechanistic network using the Ingenuity
Pathway Analysis revealed suggestive connection only for
the Zbtb16 gene. This transcriptional repressor is known to
interact with retinoic acid signaling [27] and it plays im-
portant roles in numerous and diverse processes including,
but not limited to differentiation of innate lymphocytes
[28], stem cell renewal [29] and limb patterning and
development [20,30]. We have previously shown the Lx
mutation present in the SHR-Lx congenic to result from
2.9 kb deletion of conserved noncoding element in Zbtb16
gene and to be responsible for polydactyly as well as left
ventricle hypertrophy, hypertension and insulin resistance
[12,13,20] and to sensitize towards ATRA-induced terato-
genicity [10]. In mice, complete knockout of Zbtb16 [30] as
well as spontaneous mutation (luxoid) [31] lead to infertilityand number of skeletal patterning defects. However, mice
carrying distinct missense Zbtb16 mutation were fertile in
spite of displaying hindlimb and axial skeleton abnormal-
ities [32]. Very recently, hepatic knockdown of Zbtb16 was
shown to ameliorate hyperglycemia in db/db mice [33].
Unfortunately, no data on metabolic parameters or their
sensitivity to ATRA or similar agents are available for any
of the mutant Zbtb16-carrying mouse models. Since the
only genetic difference between the two tested strains is
confined to the chromosome 8 region harboring the seven
abovementioned protein-coding genes, current data to-
gether with our previous results lead us to hypothesize that
unique separation-of-function allele of Zbtb16 in SHR-Lx
may be responsible for the observed transcriptome shifts
resulting in ATRA-induced hyperlipidemia in the SHR-Lx
congenic model. It is possible that strain-specific changes of
Zbtb16, Htr3a, Htr3b, Usp28, Zw10, Tmprss5 or Drd2 ex-
pression in other tissues (liver, adipose tissue) underlie the
observed shift of transcriptomic and metabolic profiles and
enhanced sensitivity of SHR-Lx. This belongs to one of the
limitations of the current study and multi-tissue screen of
histologically ascertained structural changes, gene expres-
sion variation and subsequent targeted functional studies
will be necessary to fully resolve the mechanism between
the observed strain-specific ATRA effects on lipid levels.
Also, since the design of our study was cross-sectional
utilizing a single dosing regimen in young adult rats to
make the results comparable to the previous experiments
involving high-sucrose diet with/without ATRA administra-
tion [11], it is possible that if older animals were used, the
metabolic effects of ATRA might be pronounced to
different extent. The modulating effect of aging on complex
disease manifestation including gene-environment interac-
tions has been described both in the SHR strain [34,35] and
the differential segment donor, the PD rat strain [36] previ-
ously. We have recently reported a significant difference of
in systolic blood pressure between the two strains used in
the current study, i.e. SHR and SHR-Lx [13]. During the
radiotelemetric measurement, the diastolic pressure did not
differ significantly between the strains neither under stand-
ard diet nor with a substantial salt load. As our study was
focused on ATRA-induced dyslipidemia, we did not run a
separate arm of the study to radiotelemetrically assess the
blood pressure. We can expect that it would be necessary
to significantly prolong the exposure of the rats to ATRA
to observe the hemodynamic effect as e.g. in the study
performed by Zhong et al. [37], where ATRA reduced the
blood pressure of SHR rats only after 3-4 weeks of
treatment.Conclusions
In summary, we have validated the SHR-Lx strain as a
model of ATRA-induced hyperlipidemia and identified
Figure 2 The cholesterol content in 20 lipoprotein subfractions in standard diet-fed (STD, open symbols) and ATRA-treated (STD + ATRA,
closed symbols) SHR (panel A) vs. SHR-Lx (panel B) male rats (n =7-8 / strain* treatment). Within the graph, the significance levels of strain
comparison (SHR vs. SHR-Lx) by post-hoc Tukey's honest significance difference test of the two-way ANOVA with STRAIN and ATRA as major factors
are indicated as follows: *…p < 0.05; **…p < 0.01; ***…p < 0.001. The allocation of individual lipoprotein subfractions to major lipoprotein classes is
shown in order of particle’s decreasing size from left to right. CM…chylomicron, VLDL…very low-density lipoprotein, LDL…low-density lipoprotein,
HDL…high-density lipoprotein.
Table 4 Lipoprotein particle size comparison control and
retinoic acid-fed SHR vs. SHR-Lx rats
Trait
(nm)
Standard diet Standard diet + ATRA
SHR SHR-Lx SHR SHR-Lx
(n = 7) (n = 7) (n = 7) (n = 8)
VLDL-TG 49.51 ± 0.45 48.24 ± 0.49 48.48 ± 0.68 50.27 ± 0.41*,a
LDL-C 21.45 ± 0.25 21.54 ± 0.11 21.77 ± 0.12 22.52 ± 0.18‡,b
HDL-C 12.20 ± 0.04 12.10 ± 0.03 12.18 ± 0.03 11.93 ± 0.05‡,c
Data are shown as mean ± S.E.M. The significance levels are indicated as
follows: a, b, c…p <0.05, 0.01 and 0.001, for differences between SHR and
SHR-Lx strains under conditions of a single diet; *, ‡… p <0.05 and 0.001,
respectively, for RA effect within individual strain.
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macogenetic interaction.
Methods
All experiments were performed in agreement with the
Animal Protection Law of the Czech Republic which is in
compliance with the European Community Council rec-
ommendations for the use of laboratory animals 86/609/
ECC and were approved by the Ethical committee of the
First Faculty of Medicine, Charles University in Prague.
Rat strains
The spontaneously hypertensive rat (SHR/OlaIpcv, SHR
hereafter, Rat Genome Database [38] RGD ID: 631848)
was originally derived by recurrent selective breeding of
Figure 3 Network analysis of pharmacogenetic interaction of RA. The figure represents the network with highest score (IPA, Ingenutiy
Systems) derived using the set of transcripts showing significant STRAIN (SHR, SHR-Lx) * ATRA (STD, STD + RA) interaction. The genes with
validated expression changes by real-time PCR are shown in green. After in silico analysis of direct and indirect connections of the genes present
within the chromosome 8 differential segment in SHR-Lx to the members of this highest-scoring network, only the Zbtb16 gene (yellow) showed
positive results.
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The SHR.PD(D8Rat42-D8Arb23)/Cub (SHR-Lx, RGD ID:
1641851) congenic strain was derived by introgressing and
subsequent narrowing down of the rat chromosome 8
differential segment of the polydactylous rat PD/Cub [18]
origin into SHR genomic background as described previ-
ously [12,13]. The Lx refers to the mutated “luxate” allele
that originally arose in outbred Wistar rat colony and was
subsequently fixed in PD/Cub strain [18]; recently, we
showed that a deletion of deeply conserved noncoding
element in Plzf (Zbtb16) is responsible for the affliction of
the limb development in Lx-bearing animals [20].
Experimental protocol
At all times, the animals had free access to food and water.
Animals were held under temperature and humidity con-
trolled conditions on 12 h/12 h light-dark cycle. Male
SHR (n = 14) and SHR-Lx (n = 15) rats were fed standard
laboratory chow ad libitum. At the age of 15 weeks, the
rats were randomly split to experimental (n = 7-8/strain)
and control (n = 7/strain) groups. All groups continued to
be fed standard diet for 16 days, and at the same time, the
experimental group was administered ATRA (15 mg/kg/day
via oral gavage) while the control group received only
vehicle via oral gavage. The food consumption, total body
weight and non-fasting glycaemia were followed daily
during this period. The rats were sacrificed in postprandialstate and the weights of heart, aorta, liver, kidneys, adrenals,
soleus muscle, epididymal and retroperitoneal fat pads were
determined and the soleus muscle was snap frozen in liquid
nitrogen for further analyses of gene expression.
Metabolic measurements
The fasting glycemia was assessed after overnight fasting at
day 14 of ATRA or vehicle administration. Blood for
glycaemia determination (Ascensia Elite Blood Glucose
Meter; Bayer HealthCare, Mishawaka, IN, validated by
Institute of Clinical Biochemistry and Laboratory Diagnostics
of the First Faculty of Medicine) was drawn from thetail
incision. . Plasma lipoproteins were analyzed by an on-line
dual enzymatic method for simultaneous quantification of
cholesterol, triacylglycerol and free glycerol by HPLC at
Skylight Biotech Inc. (Akita, Japan) according to the
procedure described previously [11,40].
Transcriptomic profiling and quantitative real-time PCR
Total RNA was extracted with TRIzol® reagent (Invitrogen,
Carlsbad, CA) and purified with the RNeasy® MinElute
cleanup kit (Qiagen, Valencia, CA) following the manufac-
turer’s recommendations. The quality of the total RNA was
evaluated on an Agilent 2100 Bioanalyzer system (Agilent,
Palo Alto, CA). Microarray experiments were performed
using the Affymetrix GeneChip® Rat Gene 2.0 ST Arrays
(Affymetrix, Santa Clara, CA) according to manufacturer’s
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ation (i.e. 12 arrays in total). The whole hybridization pro-
cedure was performed using the Affymetrix GeneChip®
system according to the protocol recommended by the
manufacturer. The hybridization was evaluated with Affy-
metrix GeneChip® Command Console Software and quality
of the chips with Affymetrix Expression Console. Partek
Genomics Suite 6.6 (Partek, St. Louis, Missouri) was used
for subsequent data analysis. The data was normalized by
Robust Multichip Average algorithm, which uses back-
ground adjustment, quantile normalization and summa
rization. To validate microarray gene expression data,
quantitative real-time PCR (TaqMan) was used. Total RNA
(2 μg) was reverse-transcribed with oligo-dT primers using
the SuperScript III (Invitrogen). The following sets of
Taqman probes (Applied Biosystems) were used: sirtuin 3
(Sirt3): Rn01501410_m1, mitochondrial elongation factor
2 (Mief2, Smcr7): Rn01495681_g1, interleukin 1 beta
(Il1b): Rn00580432_m1, carnitine palmitoyltransferase 1b,
muscle (Cpt1b): Rn00682395_m1, glutamate receptor,
ionotropic, AMPA 2 (Gria2): Rn00568514_m1, peroxi-
some proliferator-activated receptor gamma (Pparg):
Rn00440945_m1, aldehyde dehydrogenase 3 family, mem-
ber A1 (Aldh3a1): Rn00694669_m1, retinol dehydrogen-
ase 11 (all-trans/9-cis/11-cis) (Rdh11): Rn01499137_m1.
Real-time PCR reaction was performed in triplicate with
TaqMan® Gene Expression Master Mix (Applied Biosys-
tems) according to the manufacturer’s protocol (Invitrogen)
using Applied Biosystems 7000 Real-Time PCR System.
Results were analyzed using the Livak analysis method [41]
with glyceraldehyde 3-phosphate dehydrogenase as refer-
ence gene. Pathway and network analysis including assess-
ment of overrepresentation of differentially expressed
probes in canonical, metabolic and signaling pathways and
ontological classes, common regulator effects and in silico
network construction was performed using the Ingenuity
Pathways Analysis software (spring 2014 version).Statistical analysis
All statistical analyses were performed using STATISTICA
10 CZ. When comparing morphometric, biochemical and
transcriptomic variables, two-way ANOVA was used with
STRAIN (SHR; SHR-Lx) and ATRA [STD; STD +ATRA]
as major factors (Table 3 and Additional file 2: Table S1),
followed in case of biochemical and morphometric data
by post-hoc Tukey's honest significance difference test for
comparison of the specific pairs of variables. For series of
daily repeated measurements (body weight, food con-
sumption, satient glycaemia), repeated-measures ANOVA
was used. Functional analyses and canonical pathways
analyses were performed using Benjamini-Hochberg
multiple testing correction. Null hypothesis was rejected
whenever the corrected p <0.05.Additional files
Additional file 1: Figure S1. Validation of microarray results using
qPCR. Fold changes are indicated (in log2) for ATRA effect in SHR strains
(microarray: white bars; qPCR: red bars) and the SHR-Lx congenic (microarray:
black bars; qPCR: green bars). Sirt3: sirtuin 3; Smcr7: mitochondrial elongation
factor 2 (Mief2); Il1b: interleukin 1 beta; Cpt1b: carnitine palmitoyltransferase
1b, muscle; Gria2: glutamate receptor, ionotropic, AMPA 2; Pparg: peroxisome
proliferator-activated receptor gamma; Aldh3a1: aldehyde dehydrogenase
3 family, member A1; Rdh11: retinol dehydrogenase 11 (all-trans/9-cis/11-cis).
Additional file 2: Table S1. Two-way ANOVA for triacylglycerol,
cholesterol concentrations in 20 lipid subfractions (F1-F20) and
lipoprotein particle size.
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